Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined, these ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...

KRAS is one of the oncogenes most frequently altered in cancer, mutated in approximately one-third of lung adenocarcinomas.

Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...

Researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene or 'oncogene,' and how its activities impact pancreatic cancer outcomes. KRAS ...

For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just as long, they have had no way to shut it off. The protein, KRAS, mutates in ...

As reviewed above, much has been learned over the past 20 years regarding the pathways that KRAS engages and requires during lung tumorigenesis, and specific inhibitors of these downstream signaling ...

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene or "oncogene," ...